Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

By E. Ferrannini, E. Muscelli, S. Frascerra, S. Baldi, A. Mari, T. Heise, U. Broedl, H. Woerle. Journal of Clinical Investigation, 2014

987 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/637dad2c5b8f6a6f7391d575351e530fb734b1b1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. I. Hirsch
2. E. Ferrannini
3. John B. Buse
4. V. Basevi

In Surgery

1. I. Hirsch
2. E. Ferrannini
3. John B. Buse

Citations in the corpus

• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis (2016, background): “The subtraction of large amounts of glucose from the glucose pool, coupled with the dual hormonal changes, results in a 25% restriction of glucose utilization, and a concomitant increase in lipid mobilization and usage for energy production (24).”
• Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics (2017, background): “…sodium/glucose cotransporter 2 (SGLT2i) increases circulating ketone body concentrations in humans (Ferrannini et al., 2016a; Inagaki et al., 2015) and mice (Suzuki et al., 2014) via increased hepatic ketogenesis (Ferrannini et al., 2014, 2016a; Katz and Leiter, 2015; Mudaliar et al., 2015).”
• SLC Transporters as Therapeutic Targets: Emerging Opportunities (2015, positive): “Chronic dosing with empagliflozin for 4 weeks in these patients led to a significant decline in both glycated haemoglobin and fasting glucose levels 111 .”
• Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors (2015, background): “Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
• Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition (2015, background): “Furthermore, SGLT-2 inhibitors are associatedwith an increase in plasma glucagon levels throughuncertainmechanisms (19,20).”